QLGN — Qualigen Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $3.22m
- $6.86m
Annual cashflow statement for Qualigen Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 March 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 3 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-Q | 10-K | 10-K | 10-K | 10-K |
| Standards: | — | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -1.67 | -17.9 | -21 | -13.8 | -6.26 |
| Depreciation | |||||
| Non-Cash Items | -0.452 | 1.2 | 7.68 | 2.34 | 0.829 |
| Discontinued Operations | |||||
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.954 | 1.85 | -0.048 | 1.11 | -0.897 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -1.16 | -14.7 | -13.2 | -10.3 | -6.33 |
| Capital Expenditures | — | -0.141 | -0.319 | — | — |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 0 | — | 0.135 | 4.22 | -1.91 |
| Sale of Business | |||||
| Sale/Maturity of Investment | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 0 | -0.141 | -0.184 | 4.22 | -1.91 |
| Financing Cash Flow Items | -0.157 | -0.707 | 2.9 | — | 4.56 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 5.42 | 8.43 | 2.91 | -0.55 | 9.01 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 4.25 | -6.44 | -10.5 | -6.64 | 0.773 |